Navigation Links
Isis Initiates Phase 1 Study of ISIS-APOA Rx to Treat Atherosclerosis
Date:4/3/2013

keting approval of KYNAMRO in other markets.  Isis' patents provide strong and extensive protection for its drugs and technology.  Additional information about Isis is available at www.isispharm.com.

ISIS PHARMACEUTICALS' FORWARD-LOOKING STATEMENT

This press release includes forward-looking statements regarding the discovery, development, activity, therapeutic potential and safety of ISIS-APOARx.  Any statement describing Isis' goals, expectations, financial or other projections, intentions or beliefs, including the commercial potential of KYNAMRO, is a forward-looking statement and should be considered an at-risk statement.  Such statements are subject to certain risks and uncertainties, particularly those inherent in the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs.  Isis' forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements.  Although Isis' forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Isis.  As a result, you are cautioned not to rely on these forward-looking statements.  These and other risks concerning Isis' programs are described in additional detail in Isis' annual report on Form 10-K for the year ended December 31, 2012, which is on file with the SEC. Copies of this and other documents are available from the Company.

In this press release, unless the context requires otherwise, "Isis," "Company," "we," "our," and "us" refers to Isis Pharmaceuticals and its subsidiaries.

Isis Pharmaceuticals® is a registered trademark of Isis Pharmaceuticals, I
'/>"/>

SOURCE Isis Pharmaceuticals Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Anthera Initiates CHABLIS-SC1 Phase 3 Clinical Study in Lupus with Blisibimod
2. Catabasis Initiates Phase 1 Trial of CAT-2003 for Treatment of Severe Hypertriglyceridemia
3. Alliqua Initiates Life-Cycle Management Plan to Expand Wound Care Portfolio for Use in Broader Wound Indications
4. Lithera Initiates Phase 2b Clinical Trial of LIPO-202 Targeting Aesthetic Reduction of Subcutaneous Abdominal Fat
5. Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-CRP Rx In Patients With Atrial Fibrillation
6. NxStage Initiates 2013 Call to Action Campaign with Launch of Hemodialysis At Home: A Better Way For a Better Life
7. Coyote Pharmaceuticals Initiates GMP Manufacturing Process for CNS-102 Following Successful Pre-IND Meeting
8. Nanomix Initiates Clinical Testing of Point of Care IVD Cardiac Panel
9. ADVENTRX Initiates Pivotal Phase 3 Study of ANX-188
10. uniQure Initiates Phase I in Acute Intermittent Porphyria
11. Fate Therapeutics Initiates Phase 2 Clinical Study of ProHema for the Treatment of Hematologic Malignancies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/29/2015)... March 29, 2015  Three-month paliperidone palmitate, an ... compared to placebo in patients with schizophrenia, according ... this week in the Journal of ... . Results of the study served as ... (NDA) filing for three-month paliperidone palmitate injection to ...
(Date:3/27/2015)... March 27, 2015 BioCorRx, Inc. ( ... Ana, California is a healthcare solutions organization, which ... estimated at $22 billion in the U.S. alone. The Company ... FDA-approved Naltrexone in a specially compounded form for outpatient surgical ... and New Zealand ) to ...
(Date:3/27/2015)... CHAPEL HILL, N.C. , March 27, 2015 /PRNewswire/ ... function is essential to meeting challenges in clinical development, ... and face tighter regulations, the Medical Affairs function is ... charted by mature markets. According to ... market study participants have a group dedicated to Medical ...
Breaking Medicine Technology:New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 2New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 3New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 4New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 5New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 6New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 7New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 8New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 9New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 10New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 11New Study Published in JAMA Psychiatry Found Three-Month Paliperidone Palmitate Significantly Delayed Time to Relapse in Patients with Schizophrenia 12Small Cap IR Correction -- BioCorRx Inc. Positions Itself Through Strategic Partnerships To Gain Market Share Of The $22 Billion Substance Abuse Treatment Market In The U.S. 2Medical Affairs Capabilities Expanding in Emerging Marketplaces 2
... Feb. 2, 2011 WaferGen Biosystems, Inc. (OTC Bulletin ... analysis systems, today announced that it will present an overview of ... in New York City at the Waldorf Astoria Hotel, Tuesday, February ... webcast live and archived for 90 days and may be accessed ...
... 2011 Reportlinker.com announces that a new market research ... US Prebiotics Industry ... And European markets for Prebiotics in Metric Tons and ... the following product segments: Mannan-Oligosaccharide (MOS), Fructans (Fructo-Oligosaccaride (FOS), ...
Cached Medicine Technology:WaferGen to Present at 13th Annual BIO CEO and Investor Conference 2US Prebiotics Industry 2US Prebiotics Industry 3US Prebiotics Industry 4US Prebiotics Industry 5US Prebiotics Industry 6US Prebiotics Industry 7
(Date:3/28/2015)... Las Vegas, NV (PRWEB) March 28, 2015 ... correlate with a history of shoulder and elbow injuries, according ... for Sports Medicine’s ( AOSSM ) Specialty Day. , “Our ... associated with a 20% increase in likelihood of a history ... is associated with a 12% increase likelihood of a history ...
(Date:3/28/2015)... NV (PRWEB) March 28, 2015 Delaying ... not be necessary, according to research presented today at ... ) Specialty Day. , “Our study compared results for ... who underwent an additional glenohumeral joint capsule release procedure ... George Murrell MD, PhD, lead author from St. George ...
(Date:3/28/2015)... Francisco, California (PRWEB) March 28, 2015 Andrew ... for original 1960's Who psychedelic concert posters. The Who and ... New York on August 2, 1968. According to Hawley, “The ... playing many concert halls and college campuses. Perhaps the most ... performance with Jim Morrison and the Doors on August 2, ...
(Date:3/28/2015)... (PRWEB) March 28, 2015 Healthpointe’s otolaryngologists, ... nose and throat disorders, are now offering a ... common issue which is characterized by the presence of ... in 5 people, tinnitus is a prevalent symptom that ... while it is non-fatal, tinnitus can impede a person’s ...
(Date:3/28/2015)... ARDX will sponsor the 7th Annual Women’s ... the Chesapeake Conference Center in Chesapeake, Virginia. Each year, ... for women in the Hampton Roads region. The 2015 ... Lives. Women grow stronger through sharing their stories and ... year the WWC™ theme is T-talk where we will share ...
Breaking Medicine News(10 mins):Health News:Researchers Highlight Shoulder and Elbow Injury Possibility in Youth Players 2Health News:No Need to Delay Rotator Cuff Surgery, Study Shows 2Health News:Avid Collector from Vintage Rock Posters, Inc. Announces His Search For Original 1960's Who Psychedelic Concert Posters. 2Health News:Healthpointe now Offering Tinnitus Treatments in Clinics throughout Southern California 2
... Consumers need answers to questions that loom large ... is at risk.A new discussion forum launching this week ... ask tough questions and get straight answers about health ... options after a job loss."People who lose their jobs ...
... news release, Your Finances or a Facelift? It,s ... & Co Ltd over PR Newswire, we are advised ... press release was issued inadvertently. The complete, corrected release ... To DownsizeLeading Image Enhancement Coach Wendy Lewis Explains the ...
... To prevent the rejection of newly transplanted ... weaken their entire immune systems. Such potentially life-saving ... to life-threatening infections. , Now researchers at ... School of Medicine and the UNC Lineberger Comprehensive ...
... 11, 2009 "The House of Representatives and the ... ,down payment, on health care reform in the economic ... the American College of Physicians, said today. ... agreement that will provide adequate funding for critical health ...
... Feb. 11 Mesa Laboratories, Inc. (Nasdaq: ... of Directors has declared a regular quarterly cash ... stock, payable on March 16, 2009 to shareholders ... February 27, 2009.Mesa Laboratories develops, acquires, manufactures and ...
... Fresenius Kabi Pty Ltd, one of Australia,s fastest growing ... System (Robotic IV Automation) - a self-contained unit for ... Systems (IH Systems) to consolidate its IV preparation. Pharmatel ... unit in June 2009. , The RIVA System and ...
Cached Medicine News:Health News:C4CC Education Fund Launches Discussion Forum for Consumers With Health Insurance Questions 2Health News:Your Facelift or Your Finances? It's Time To Downsize 2Health News:UNC study hints at new approaches to prevent transplant rejection 2Health News:UNC study hints at new approaches to prevent transplant rejection 3Health News:ACP commends Congress for including health care reform in economic stimulus legislation 2Health News:Australia's Leading Oncology Drug Compounder Chooses RIVA System 2
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: